D
espite nearly two decades of experience in the field, the clinical practice of lung transplantation (LT) varies greatly among transplant centers. Prospective, randomized clinical trials have been performed primarily in single centers with few patients participating. This has limited evidence-based improvements in the standardization of management. However, new immunosuppressive agents and anti-infective strategies, which have been demonstrated to be effective in other solid organ transplants, have been widely adopted, and the management of lung transplant recipients has evolved significantly.
In 1998, guidelines for the selection of patients for LT were established by a consensus conference with representatives from several professional thoracic and transplant societies. 1 While widely quoted and referenced, this document stressed that the criteria were only "guidelines," and permitted the possibility of variability in clinical practice among centers.
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Consensus standards for the postoperative management of lung transplant recipients have not been published. To assess the variability in both the selection of candidates for and the postoperative management of lung transplants throughout North America, the Transplant/Immunology Network of the American College of Chest Physicians (ACCP) completed a questionnaire survey of LT practices in the United States and Canada.
Materials and Methods
The survey was based on a survey sent to Canadian lung transplant programs in 1998. Using the Canadian survey as a template, the Transplant/Immunology Network Steering Committee expanded and refined the survey. The nine members of the steering committee piloted the survey. A final version consisted of 64 questions covering patient selection and postoperative management issues (see "Appendix"). The respondents were requested "to answer the survey to reflect the current way LT is practiced at your transplant program."
Using an online survey tool (www.surveymonkey.com), the survey was disseminated to each listed program director of all lung transplant centers listed in September 2001 by the United Network of Organ Sharing (UNOS). The survey was distributed on September 4, 2002, and was closed on October 20, 2002. Seventy-nine centers were listed as being active by UNOS at the time of the mailing. In addition, the survey was sent to the five active Canadian centers. Only one survey was sent to each center. Those answering the survey had the option to remain anonymous.
The survey responses were tabulated by online software (www. surveymonkey.com) and then were placed into a data spreadsheet for further analysis. The data are presented in a simple graphic format as percentages of respondents. For some questions, a subanalysis of program practices at smaller centers (defined as programs performing Ͻ 30 LT procedures per year) and larger centers (defined as programs performing Ն 30 LT procedures per year) was performed.
Results
Eighty-four surveys were distributed (UNOS centers, 79 survey; Canadian centers, 5 surveys). A total of 54 centers (64%) responded. On follow-up phone calls, 15 centers, although listed as being active by UNOS, indicated that they were inactive. Four centers had two UNOS listings. After adjusting for four duplications, there were 50 single responders from 65 active North American programs, a 77% response rate. Of the 15 nonresponders to the distribution of the survey, three were pediatric-only programs. Among the responders, the average number of lung transplants performed per year was 22, with a range of 1 to 55 transplants performed per year (Fig 1) . The 50 respondents identified themselves as pulmonologists (75%), surgeons (19%), coordinators (4%), and other (2%).
Patient Selection
The first section of the survey focused on issues in the selection of patients for LT, including the following: tobacco use; medical noncompliance; history of lung cancer; psychiatric diagnoses; coronary artery disease (CAD); infection; age limitations; mechanical ventilation; osteoporosis and osteopenia; weight limitations; and exercise capacity.
As shown in Figure 2 , the majority of programs surveyed considered ongoing smoking, a demonstrated history of noncompliance with medical regimens, and a history of localized malignancies (other than nonmelanoma skin) within the prior 2 years to be absolute or relative contraindications to transplantation. Correctable CAD and psychiatric diagnoses, other than anxiety or depression, requiring active treatment were considered relative contraindications to transplantation by most programs.
Infection
Colonization with resistant organisms, particularly in the cystic fibrosis population, often poses a dilemma for the transplant physician due to concerns of disseminated infection, sepsis, and poor outcomes in the posttransplant period. Several small studies [2] [3] [4] [5] have examined this subject, focusing on resistance patterns, antibiotic synergy results, and genomovar analysis. Figure 3 shows program approaches to patients who are colonized with Burkholderia cepacia. When questioned about colonization with Pseudomonas aeruginosa, 35% of programs based their transplant decision on the results of synergy testing and 22% based it on sensitivity results, while 29% of programs stated that this was not a contraindication and 14% considered this an absolute contraindication to transplantation. For colonization with atypical mycobacterial infections, 59% of programs considered this to be a relative contraindication, 6% an absolute contraindication, and 35% not a contraindication to transplantation. Program policies were widely divergent with respect to these organisms, but B cepacia was the organism most often considered to be an absolute contraindication. HIV infection was an absolute contraindication at most centers (96%) but, of interest, not at all centers (4% reported HIV infection to be a relative contraindication).
The approach to potential recipients who are hepatitis C-seropositive varies among centers. Many programs select these candidates based on the re- sults of liver biopsy specimen examinations (43%), while 35% and 22%, respectively, of programs viewed this as a relative and absolute contraindication.
Mechanical Ventilation
Mechanical ventilation has long been considered to be a strong relative contraindication to transplantation due to concerns about nosocomial organism colonization and potential infection. We chose to divide this question into the following three groups: patients with acute respiratory failure requiring mechanical ventilation; patients with chronic respiratory failure (CRF) requiring mechanical ventilation; and patients receiving noninvasive mechanical ventilation. The results are shown in Figure 4 . Most programs considered mechanical ventilation for acute or CRF to be an absolute or relative contraindication to LT, but most programs considered noninvasive mechanical ventilation not to be a contraindication.
Age Limits
The 1998 consensus guidelines 1 suggested an upper age limit of 55 years for heart LT (HLT), 60 years for bilateral LT (BLT), and 65 years for single LT (SLT). Actual practices in centers are shown in Figure 5 and, in general, reflect the guidelines. Age limits were similar among smaller and larger centers.
Pulmonary Hypertension
Earlier data suggested that SLT recipients who received transplants because of pulmonary hypertension may have a difficult postoperative course as well as a poor outcome during periods of graft complications. 6 However, subsequent registry data suggested comparable survival rates between SLT and BLT recipients by 5 years posttransplant. 7, 8 A specific scenario thought to represent a difficult clinical decision was posed about the transplant procedure of choice for a 50-year-old patient with primary pulmonary hypertension and a right ventricular ejection fraction of 20%. Responses (Fig 6) were divided between BLT preferred (39%) and BLT only (42%) for this scenario, with only a few centers preferring SLT or HLT in this situation.
Body Weight
Studies have suggested that extremes of body weight can impact survival following LT. 9, 10 The majority of transplant centers surveyed (79%) had upper and lower limits for body weight at their programs. Those that had limits were near equally divided between using body mass index (54%) vs an ideal body weight (46%) as the metric for their criteria. For the upper limits, the majority of centers used either an ideal body weight of Ͼ 130% of predicted or a body mass index of Ͼ 30 kg/m 2 . A smattering of programs used Ͼ 120% or 125% of ideal body weight as the upper limits for body weight, and a small percentage of programs used a body mass index of Ͼ 30 or 35 kg/m 2 as their upper limit. For lower limits of body weight, the majority of respondents used an ideal body weight of Ͻ 70 to 80% of predicted. A number of programs used a body mass index of Ͻ 15 to 18 kg/m 2 as their limit for transplantation. Additional single write-in responses included "varies by gender," "no limits," or "individualized to patient."
Exercise Capacity
The slight majority of programs (58%) had a minimum requirement for exercise capacity to be considered for LT. When questioned about specific exercise requirements, responses included 6-min walk test distances of 250 to 1,000 feet or 100 to 300 m. Six hundred feet attained on a 6-min walk test was the highest frequency response.
Because of the importance of postoperative rehabilitation and conditioning, a scenario was posed as to the transplant candidacy of a patient with minimal ability to ambulate, which was defined as only being able to transfer from bed to chair. The responses were divided between considering this to be a relative contraindication to transplantation (52%) vs an absolute contraindication (46%), and only one respondent thought that this was not a contraindication to transplantation.
Osteoporosis
The problem of transplant osteoporosis has been well-described due to both corticosteroid use as part of posttransplant immunosuppression as well as corticosteroid use in treating chronic lung diseases preoperatively, which was further compounded by immobilization, and, in the case of cystic fibrosis, malabsorption. 10 -12 The vast majority of centers (87%) perform routine pretransplant bone densitometry. The presence of osteoporosis on bone densitometry alone was considered to be a relative but not an absolute contraindication to transplantation at 84% of centers and not a contraindication at 16% of centers. However, the presence of osteoporosis and spinal fractures was considered to be a relative contraindication (75%) or an absolute contraindication (23%) at nearly all centers.
Common treatments for patients with osteoporosis included the following: supplemental calcium (96%); supplemental vitamin D (85%); oral bisphosphonates (94%); and IV bisphosphonates (25%) [Fig 7] . Other individual answers included calcitonin therapy as well as hormone replacement therapy. Similar treat- 
Lung Preservation
Adequate lung preservation is considered essential to good outcomes, but many different preservation solutions and approaches to preservation exist. Thus, we posed a question about the use of the most commonly available solutions. The most commonly used preservation solution was low potassium dextran (46%) [Perfadex; Vitrolife AB; Gothenburg, Germany], followed by University of Wisconsin solution (22%), modified Euro-Collins solution (18%), Celsior (12%) [SangStat Medical Corp; Fremont, CA], and Euro-Collins solution (2%).
Posttransplantation Care
The second half of the survey concentrated on posttransplant practices, including maintenance immunosuppression, the management of acute and chronic rejection, the prophylaxis for cytomegalovirus (CMV) and fungal infections, the management of posttransplant lymphoproliferative disorders, and routine surveillance studies.
Nitric Oxide
The salvage or routine use of nitric oxide (NO) in the immediate perioperative period has been proposed by several studies [13] [14] [15] to treat or ameliorate the pulmonary reimplantation response. We queried programs about the use of NO in this setting. The indications for the use of NO varied significantly among programs. Thirty-three percent of programs used NO for reperfusion injury, 27% for pulmonary hypertension, 27% never or rarely used NO, and 13% reported routine use of NO. (Note that respondents were not permitted to choose more than one indication for NO use.)
Induction Immunosuppression
Induction therapy was used routinely in approximately one half of the programs surveyed, which is similar to data reported by the International Society of Heart Lung Transplantation registry. 16 (Fig 8) No center reported the use of OKT3 for induction therapy. The use of induction therapy was similar among smaller and larger centers.
Maintenance Immunosuppression
The initial maintenance immunosuppression at the programs surveyed was almost equally divided between several triple immunosuppressive regimens (Fig 9) . All regimens contained corticosteroids, a calcineurin inhibitor, and a cell cycle inhibitor. The combination of prednisone, tacrolimus (Tac), and mycophenolate mofetil (MMF) was the most common. The distribu- tion of maintenance immunosuppression regimens was similar among smaller centers and larger centers, with a slight predominance of a prednisone, Tac, and MMF regimen at the smaller centers, and a slight predominance of a prednisone, Tac, and azathioprine (AZA) regimen at the larger centers.
Acute Rejection
The preferred initial treatments of acute rejection of grade A2 or greater are shown in Figure 10 . All centers stated that the first episode of grade A2 or greater acute rejection was treated with a short course of augmented IV or oral corticosteroids. Other interventions included increasing levels of maintenance corticosteroids or calcineurin inhibitors, with a few programs switching immunosuppressive agents.
For recurrent or persistent acute rejection of grade A2 or greater (Fig 11) , the majority of programs used short-course augmented IV or oral corticosteroids. Other common interventions included switching calcineurin or cell cycle inhibitor agents, and enhancing maintenance immunosuppression. Nearly one third of programs initiated rapamycin therapy or a course of lympholytic therapy with antilymphocyte globulin (ALG)/antithymocyte globulin (ATG) for recurrent or persistent acute rejection. Other therapies included photopheresis (8%), methotrexate (6%), and OKT3 (6%).
Chronic Rejection
Chronic rejection or bronchiolitis obliterans remains the major impediment to prolonged survival following LT. Nearly 50% of long-term survivors (ie, Ͼ 5 years) will develop bronchiolitis obliterans syndrome (BOS). 16 Because of the notoriously poor response to augmented immunosuppression for the treatment of BOS, the survey inquired about the usual order of interventions (from 1 to 12 with concurrent interventions permitted in the response) for treatment of this disorder. The results for first-line and secondline interventions are shown in Figure 12 .
For first-line therapy of BOS, 65% of respondents used short-course corticosteroids, and 27% changed to therapy with calcineurin inhibitors from cyclosporine (CSA) to Tac. Other first-line interventions included changing AZA to MMF, instituting a short course of therapy with augmented oral corticosteroids, increasing the dose of therapy with maintenance corticosteroids or calcineurin inhibitors, or adding inhaled corticosteroids to the regimen. Sixteen percent of programs started with rapamycin as a first-line treatment for BOS. Other interventions included lympholytic therapy and methotrexate. The use of rapamycin as a first-line or second-line therapy for BOS was similar among smaller and larger centers.
Subsequent interventions were notable for the infrequent use of corticosteroids, as more programs preferred to change immunosuppressive agents from CSA to Tac or to increase maintenance immunosuppressive levels. Some programs reserved rapamycin or methotrexate therapy for third-line or fourth-line treatment of chronic rejection. Several programs initiated a course of lympholytic therapy (specifically ATG/ALG) as second-line therapy for BOS. Other responses (data not shown) included the following: photopheresis; azithromycin; evaluation for gastroesophageal reflux disease; and total lymphoid irradiation. One respondent reported the use of IV cyclophosphamide.
For progressive bronchiolitis obliterans or BOS not responding to the above measures (Fig 13) , retransplantation was considered in 55% of programs, inhaled corticosteroids were used by 25%, methotrexate were used by 18%, total lymphoid irradiation were used 18%, and inhaled CSA was used by 10%. Of interest, 63% of programs initiated antibiotic treatment for chronic infection associated with progressive or refractory BOS. Photopheresis was used by a significant number of centers, and leflunomide was listed by one center.
Surveillance Bronchoscopy
A question was posed regarding surveillance bronchoscopy, which remains a controversial area in LT. 17, 18 Sixty-nine percent of centers polled perform surveillance bronchoscopy, which is nearly identical to the 68% reported in a 1997 survey specifically addressing this question. 17 Of those centers that do perform bronchoscopy, the time intervals between bronchoscopy procedures vary, but they were most commonly performed at 1, 3, 6, and 12 months posttransplant. Other protocols included bronchoscopy at 1 week, 1 month, 3 months, 6 months, and 1 year, and others performed the first bronchoscopy at 2 weeks following LT, then at 6 weeks, and at 3, 6, 9, 12, 18, and 24 months following LT. Thirty percent of programs answering this question continue surveillance bronchoscopy until 2 years following LT. Only 8% of programs continued surveillance bronchoscopy beyond the 2-year point. Thirty-one percent of programs perform bronchoscopy for clinical indications only. Figure 14 shows the varied approaches to CMV prophylaxis and treatment among the three permutations of donor and recipient CMV serology. Routine prophylaxis for the CMV-negative donor/CMVnegative recipient is most commonly performed with oral acyclovir at 42% of centers. Twenty-two percent of centers do not use prophylaxis in this negative/ negative subgroup. Other agents that were used included valganciclovir, IV or oral ganciclovir, and CMV hyperimmune globulin. Acyclovir was most commonly given for 12 weeks and valganciclovir for 2 to 12 weeks following LT, although some programs prescribed acyclovir for a year or for life. Monitoring for CMV infection in this CMV subgroup was performed with quantitative polymerase chain reaction (PCR) at 22% of programs and CMV antigenemia at 16%.
CMV Prophylaxis
In the CMV-positive recipient, IV or oral ganciclovir or valganciclovir was used most commonly (48%, 24%, and 52%, respectively). Oral ganciclovir or acyclovir was used by some programs, and 10% of programs used CMV hyperimmune globulin. The duration of action of IV ganciclovir is usually shorter than that in the mismatch group, ranging on average from 1 to 8 weeks. Valganciclovir or oral ganciclovir was used on average from 12 weeks to a year, or occasionally indefinitely. Monitoring with surveillance antigenemia or quantitative PCR was similar to that of the other groups.
In the high at-risk group, the mismatch of a CMV-positive donor/CMV-negative recipient, 72% of centers use IV ganciclovir (at least initially) for prophylaxis, more than half use valganciclovir for prolonged prophylaxis, and more than half use CMV hyperimmune globulin. The duration of prophylaxis included, most commonly, IV ganciclovir for 1 to 3 months followed by or changed to oral ganciclovir or valganciclovir for 3 months to 1 year, or, in several programs, indefinite treatment. CMV hyperimmune globulin was administered for, most commonly, 12 to 16 weeks. Thirty percent of centers monitor with CMV antigenemia and 20% use CMV PCR.
Epstein-Barr Virus Monitoring
Eighty-two percent of programs routinely determine donor and recipient Epstein-Barr virus (EBV) serologic status, although only 8% of programs attempt EBV matching when performing transplantation. Seventy-nine percent of programs do not require blood products screened for EBV in the event of a negative-negative donor-recipient. Although one third of programs follow EBV quantitative PCR levels, nearly 50% do not make management decisions based on the results. Several programs reported the use of acyclovir or oral ganciclovir for 6 to 12 months or lifetime in the EBV mismatch group. EBV status is rarely used (16% of the time) to alter immunosuppressive protocol. The prophylactic regimens for EBV mismatches used at different programs are shown in Figure 15 . 
Antifungal Prophylaxis
Eighty percent of respondents use antifungal prophylaxis in their programs. The prophylactic agents used are shown in Figure 16 . Of the agents used, inhaled amphotericin, itraconazole, and fluconazole were most frequent. The typical duration for azole prophylaxis ranges from 12 weeks to indefinite use. Inhaled amphotericin was used most commonly for 4 weeks, and at some centers was administered only to patients with cystic fibrosis.
Annual Routine Medical Surveillance
The percentage of programs performing recommended surveillance for medical conditions following transplantation are shown in Figure 17 . Surveillance studies that were commonly performed included pulmonary function testing, mammography, Pap smears, and prostate specific antigen tests. Nearly three quarters of programs performed bone densitometry testing. Twenty-four percent of programs performed echocardiography routinely. A third of programs performed routine dermatologic evaluations. Other tests performed include chest CT scans (36%), colonoscopy (16%), exercise testing, ventilation perfusion scanning, and cardiac stress testing.
Retransplantation
A series of questions was asked about retransplantation. Ninety percent of programs perform retrans- plantation, and of these, half will perform retransplantation for chronic rejection, 5% for etiologies other than chronic rejection, and 45% will perform retransplantation for chronic rejection as well as other etiologies. Ten percent of programs do not perform retransplantation.
Living Donor Transplantation
A final question asked centers about plans to develop a living donor transplant program over the next 5 years. The majority of centers (62%) indicated that they would like to develop such a program.
Conclusions
The ACCP Transplant/Immunology Network is aware that this survey is a time-sensitive snapshot of the patterns of practice in North American LT, but, to our knowledge, this is the first such comprehensive assessment of clinical practice in the field. Undoubtedly, with the rapid emergence of new technologies, these practices will evolve. It is important to emphasize that this is not a series of recommendations on the practice of LT but is merely a survey of the current practice of LT in North America. Thus, it is subject to the inaccuracies of survey methodology. Our attempt is to focus on real-world practice problems that are of significant practical value to the readership.
This study also emphasizes the potential power of a network project. Although this originated from a relatively small network, the Web-based technologies allowed rapid data collection and analysis. Although surveys previously have been conducted on specific aspects of LT, including surveillance bronchoscopy 17 and issues related to quality of life, 19, 20 this is the first-ever comprehensive survey of LT practices across the strong majority of lung transplant centers in North America.
The results were striking both for the areas of concurrence and consensus, as well as for the areas of variance and controversy. Perhaps the areas of controversy highlighted in this article will serve to foster collaborative research in these areas.
